- Home
- NKTX vs WEA Comparison
NKTX vs WEA Comparison
Compare NKTX & WEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- WEA
- Stock Information
- Founded
- NKTX 2015
- WEA 2002
- Country
- NKTX United States
- WEA United States
- Employees
- NKTX N/A
- WEA N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- WEA Trusts Except Educational Religious and Charitable
- Sector
- NKTX Health Care
- WEA Finance
- Exchange
- NKTX Nasdaq
- WEA Nasdaq
- Market Cap
- NKTX 123.5M
- WEA 129.0M
- IPO Year
- NKTX 2020
- WEA N/A
- Fundamental
- Price
- NKTX $1.77
- WEA $10.77
- Analyst Decision
- NKTX Strong Buy
- WEA
- Analyst Count
- NKTX 6
- WEA 0
- Target Price
- NKTX $14.40
- WEA N/A
- AVG Volume (30 Days)
- NKTX 422.2K
- WEA 46.1K
- Earning Date
- NKTX 08-12-2025
- WEA 01-01-0001
- Dividend Yield
- NKTX N/A
- WEA 7.87%
- EPS Growth
- NKTX N/A
- WEA N/A
- EPS
- NKTX N/A
- WEA N/A
- Revenue
- NKTX N/A
- WEA N/A
- Revenue This Year
- NKTX N/A
- WEA N/A
- Revenue Next Year
- NKTX N/A
- WEA N/A
- P/E Ratio
- NKTX N/A
- WEA N/A
- Revenue Growth
- NKTX N/A
- WEA N/A
- 52 Week Low
- NKTX $1.31
- WEA $9.60
- 52 Week High
- NKTX $8.23
- WEA $11.29
- Technical
- Relative Strength Index (RSI)
- NKTX 46.34
- WEA 53.64
- Support Level
- NKTX $1.76
- WEA $10.60
- Resistance Level
- NKTX $2.08
- WEA $10.86
- Average True Range (ATR)
- NKTX 0.11
- WEA 0.11
- MACD
- NKTX -0.00
- WEA 0.00
- Stochastic Oscillator
- NKTX 25.00
- WEA 60.00
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.